TG Therapeutics
TGTX
$46.17
-11.26%
TG Therapeutics is a fully integrated, commercial-stage biotechnology company focused on developing and commercializing novel treatments for B-cell diseases, with its lead product BRIUMVI (ublituximab-xiiy) approved for relapsing forms of multiple sclerosis (RMS). The company has established itself as a niche player in the MS treatment landscape, leveraging its anti-CD20 monoclonal antibody to compete with established therapies. The current investor narrative centers on the rapid commercial ramp of BRIUMVI, which has driven substantial revenue growth and a transition to profitability, while the company continues to expand its pipeline and geographic reach. Recent attention has been fueled by strong quarterly results and a significant stock price appreciation, reflecting optimism about sustained growth and market share gains.…
TGTX
TG Therapeutics
$46.17
Investment Opinion: Should I buy TGTX Today?
We rate TGTX as a Buy, given its explosive revenue growth, strong profitability, and attractive valuation on a trailing basis. The consensus Strong Buy rating and average target price of $68.43 imply 31.5% upside, supporting the bullish thesis. The company's ability to grow revenue by 69.6% YoY while maintaining a 83.7% gross margin demonstrates strong commercial execution.
Sign up to view all
TGTX 12-Month Price Forecast
The AI model is bullish on TGTX due to its exceptional revenue growth and profitability, but the negative free cash flow and high forward PE temper confidence. The stock's low trailing PE suggests it is undervalued relative to current earnings, but the market's expectation of lower future earnings is a red flag. If the company can sustain growth and improve cash flow, the stock has significant upside. However, any sign of deceleration or cash burn could trigger a sharp correction. The stance would be upgraded to high confidence if free cash flow turns positive and revenue growth remains above 50%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TG Therapeutics's 12-month outlook, with a consensus price target around $68.43 and implied upside of +48.2% versus the current price.
Average Target
$68.43
0 analysts
Implied Upside
+48.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$20 - $86
Analyst target range
The target price range spans from $20.00 to $86.00, a wide spread that reflects high uncertainty about the company's future. The low target of $20.00 implies a 61.6% downside, likely pricing in competitive pressures or regulatory setbacks, while the high target assumes successful expansion and multiple expansion. Recent ratings actions have been mostly reaffirmations, with HC Wainwright reiterating Buy in July 2026, and B of A Securities maintaining an Underperform, indicating a divergence in views. The wide range and mixed opinions suggest that while the consensus is bullish, there is significant risk, and investors should carefully consider the potential for volatility.
Bulls vs Bears: TGTX Investment Factors
TG Therapeutics presents a compelling growth story with explosive revenue growth, strong margins, and a low trailing PE, but the forward PE and negative free cash flow raise concerns about earnings sustainability. The bull case is supported by robust commercial execution and analyst optimism, while the bear case highlights valuation uncertainty and competitive risks. Currently, the bull evidence is stronger given the revenue momentum and profitability, but the wide analyst target range and high volatility warrant caution. The key tension is whether the company can sustain its growth trajectory and convert revenue into consistent free cash flow, which would validate the current valuation and support further upside.
Bullish
- Explosive Revenue Growth: Q1 2026 revenue surged 69.6% YoY to $204.9M, driven by BRIUMVI sales of $201.3M. This rapid commercial ramp demonstrates strong market adoption and positions the company for continued expansion.
- Strong Profitability and Margins: Gross margin is 83.7%, and the company achieved a net margin of 9.7% in Q1 2026, with positive net income of $19.8M. This indicates efficient cost management and a scalable business model.
- Attractive Valuation on Trailing PE: The trailing PE of 9.6x is low for a biotech growing at this pace, suggesting the market may be undervaluing current earnings. The PEG ratio of 0.005 further highlights the disconnect between price and growth.
- Strong Analyst Consensus: With a Strong Buy rating and an average target price of $68.43, analysts see 31.5% upside from the current price of $52.03. The high target of $86 implies even greater potential.
Bearish
- Wide Analyst Target Range: The target price range spans from $20 to $86, with the low target implying a 61.6% downside. This wide dispersion reflects significant uncertainty and potential for sharp corrections.
- High Valuation on Forward PE: The forward PE of 15.9x is higher than the trailing PE, suggesting the market expects earnings to decline. This unusual pattern could indicate one-time gains or rising expenses ahead.
- Negative Free Cash Flow: TTM free cash flow is -$14.2M, indicating the company is still burning cash despite reported profitability. This could pressure liquidity if growth slows.
- High Beta and Volatility: With a beta of 1.6, the stock is significantly more volatile than the market. The max drawdown of -32.7% over the past year highlights the risk of large losses.
TGTX Technical Analysis
TG Therapeutics has been in a powerful uptrend over the past year, with the stock surging 46.56% over the last 12 months, significantly outperforming the S&P 500's 18.19% gain. The current price of $52.03 sits at 87.7% of its 52-week range (between $25.28 and $59.30), indicating the stock is trading near its highs, which suggests strong momentum but also potential overextension. The 52-week low was set in early 2026, and the stock has more than doubled from that level, reflecting a robust recovery and sustained investor confidence.
Beta
1.67
1.67x market volatility
Max Drawdown
-32.7%
Largest decline past year
52-Week Range
$25-$59
Price range past year
Annual Return
+31.8%
Cumulative gain past year
| Period | TGTX Return | S&P 500 |
|---|---|---|
| 1m | -13.4% | +1.7% |
| 3m | +27.9% | +4.7% |
| 6m | +58.6% | +10.4% |
| 1y | +31.8% | +21.9% |
| ytd | +57.7% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TGTX Fundamental Analysis
TG Therapeutics has demonstrated exceptional revenue growth, with Q1 2026 revenue of $204.9 million, representing a 69.56% year-over-year increase from $120.9 million in Q1 2025. This growth is driven primarily by BRIUMVI product sales, which contributed $201.3 million in Q1 2026, up from $120.9 million in the prior year quarter. The company has also shown sequential growth, with revenue increasing from $192.6 million in Q4 2025 to $204.9 million in Q1 2026, indicating accelerating commercial adoption. The revenue trajectory is robust, and the company's ability to sustain this growth will be critical to its investment thesis.
Quarterly Revenue
$204918000.0B
2026-03
Revenue YoY Growth
+69.6%
YoY Comparison
Gross Margin
83.7%
Latest Quarter
Free Cash Flow
$-14191000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TGTX Overvalued?
Given that TG Therapeutics is profitable with a trailing net income of $19.8 million, the PE ratio is the most appropriate valuation metric. The trailing PE stands at 9.62x, while the forward PE is 15.86x, implying that the market expects earnings to decline in the near term, which is unusual for a growth company. This gap suggests that the current earnings may be inflated by one-time items or that analysts project higher expenses ahead. The PEG ratio of 0.005 is extremely low, indicating that the stock is undervalued relative to its growth rate, but this metric may be distorted by the high growth rate.
PE
9.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~96x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include the negative free cash flow of -$14.2M TTM, which indicates that despite reported net income, the company is not generating cash from operations. This could lead to liquidity issues if growth slows or expenses rise. The debt-to-equity ratio of 0.40 is moderate, but interest expenses of $7.7M in Q1 2026 consume a portion of operating income. Additionally, the forward PE of 15.9x is higher than the trailing PE, suggesting that earnings may decline, possibly due to increased R&D or marketing spending. The company's reliance on a single product, BRIUMVI, for nearly all revenue (98% in Q1 2026) creates concentration risk if sales falter.